U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Details

Stereochemistry ABSOLUTE
Molecular Formula C32H43N5O4
Molecular Weight 561.7149
Optical Activity UNSPECIFIED
Defined Stereocenters 4 / 4
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of SM-433

SMILES

CN[C@@H](C)C(=O)N[C@H]1CN(CC[C@H]2CC[C@H](N2C1=O)C(=O)NCC3=CC=CC=C3C4=CC=CC=C4)C(=O)CC(C)C

InChI

InChIKey=SZVCBOBNBHXZKC-MZRLSVQCSA-N
InChI=1S/C32H43N5O4/c1-21(2)18-29(38)36-17-16-25-14-15-28(37(25)32(41)27(20-36)35-30(39)22(3)33-4)31(40)34-19-24-12-8-9-13-26(24)23-10-6-5-7-11-23/h5-13,21-22,25,27-28,33H,14-20H2,1-4H3,(H,34,40)(H,35,39)/t22-,25+,27-,28-/m0/s1

HIDE SMILES / InChI

Molecular Formula C32H43N5O4
Molecular Weight 561.7149
Charge 0
Count
MOL RATIO 1 MOL RATIO (average)
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 4 / 4
E/Z Centers 0
Optical Activity UNSPECIFIED

Description

AT-406 (DEBIO-1143, SM-406), is a potent and orally bioavailable Smac mimetic and an antagonist of the inhibitor of apoptosis proteins (IAPs). AT-406 inhibits cancer cell growth in various human cancer cell lines. It has good oral bioavailability in mice, rats, non-human primates, and dogs, is highly effective in induction of apoptosis in xenograft tumors, and is capable of complete inhibition of tumor growth. Debiopharm under a licence from Ascenta Therapeutics is developing AT-406 for the treatment of cancers.

Originator

Approval Year

Targets

Primary TargetPharmacologyConditionPotency
66.4 nM [Ki]
1.9 nM [Ki]
5.1 nM [Ki]

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Unknown
Primary
Unknown
Primary
Unknown
Primary
Unknown
Primary
Unknown

Cmax

ValueDoseCo-administeredAnalytePopulation
10300 ng/mL
900 mg 1 times / day multiple, oral
AT-406 plasma
Homo sapiens

AUC

ValueDoseCo-administeredAnalytePopulation
47000 ng × h/mL
900 mg 1 times / day multiple, oral
AT-406 plasma
Homo sapiens

T1/2

ValueDoseCo-administeredAnalytePopulation
3.15 h
900 mg 1 times / day multiple, oral
AT-406 plasma
Homo sapiens

Funbound

ValueDoseCo-administeredAnalytePopulation
19%
AT-406 plasma
Homo sapiens

Doses

PubMed

Sample Use Guides

In Vivo Use Guide
5 to 900 mg AT406 (DEBIO1143) was given orally once daily on days 1-5 every 2 or 3 weeks until disease progressed or patients dropped out: DEBIO1143 was well tolerated at doses up to 900 mg and elicited pharmacodynamics effects at doses greater 80 mg.
Route of Administration: Oral
In Vitro Use Guide
AT-406 potently inhibits cell growth in the MDA-MB-231 breast and SK-OV-3 ovarian cancer cell lines with IC50 = 144 nM and 142 nM, respectively. AT-406 effectively induces cell death in a time- and dose-dependent manner, more than 50% of the MDA-MB-231 cancer cells underwent cell death upon treatment at 1 μM for 24 hours.
Substance Class Chemical
Record UNII
DH7Q8HYP47
Record Status Validated (UNII)
Record Version